Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Revathi Ananthakrishnan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Therapeutic Innovation & Regulatory Science|August 5, 2025
Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical TrialsPhilip He, Haijun Ma, Chengxing Cindy Lu, et al.
Journal of Drug Assessment|September 30, 2017
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphomaRandeep Sangha, Andrew Davies, Nam H Dang, et al.
Cancer Medicine|May 27, 2022
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomaShinichi Makita, Go Yamamoto, Dai Maruyama, et al.
Biophysical Journal|February 22, 2005
Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competenceJochen Guck, Stefan Schinkinger, Bryan Lincoln, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumorsSheri L Spunt, Stephan A Grupp, Terry A Vik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerLecia V Sequist, Benjamin Besse, Thomas J Lynch, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumorsLeena Gandhi, Rastislav Bahleda, Sara M Tolaney, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Therapeutic Innovation & Regulatory Science|August 5, 2025
Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical TrialsPhilip He, Haijun Ma, Chengxing Cindy Lu, et al.
Journal of Drug Assessment|September 30, 2017
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphomaRandeep Sangha, Andrew Davies, Nam H Dang, et al.
Cancer Medicine|May 27, 2022
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomaShinichi Makita, Go Yamamoto, Dai Maruyama, et al.
Biophysical Journal|February 22, 2005
Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competenceJochen Guck, Stefan Schinkinger, Bryan Lincoln, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumorsSheri L Spunt, Stephan A Grupp, Terry A Vik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerLecia V Sequist, Benjamin Besse, Thomas J Lynch, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumorsLeena Gandhi, Rastislav Bahleda, Sara M Tolaney, et al.
Pageof 3